Leukemia, Myelomonocytic, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
TET2 functions as a bona fide tumor suppressor particularly in the pathogenesis of myeloid malignancies resembling chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) in human.
|
25510268 |
2015 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We detected TET2 mutations in 44 of 88 (50%) patients with chronic myelomonocytic leukemia, which suggests that TET2 gene mutations are especially frequent in this myeloid disease.
|
19797729 |
2009 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Exome sequencing studies in chronic myelomonocytic leukemia (CMML) illustrate a mutational landscape characterized by few somatic mutations involving a subset of recurrent gene mutations in ASXL1, SRSF2, and TET2, each approaching 40% in incidence.
|
27707735 |
2016 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
|
20693430 |
2010 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We screened 45 patients with chronic myelomonocytic leukemia (n = 39 patients, including seven with transformed-acute myeloid leukemia), MDS/MPN unclassifiable (n = 5), and atypical BCR-ABL1-negative CML (n = 1) for mutations in ASXL1, CBL, NRAS, and TET2 genes by molecular genetics including a sensitive next-generation sequencing (NGS) technique.
|
24164563 |
2014 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
We identified cases which either: (1) fulfilled the 2008 World Health Organization criteria for primary myelofibrosis but had absolute monocytosis and, when available, chronic myelomonocytic leukemia-related mutations (ASXL1, SRSF2, TET2) or (2) fulfilled criteria of chronic myelomonocytic leukemia but had megakaryocytic proliferation and atypia, marrow fibrosis, and myeloproliferative-type driver mutations (JAK2, MPL, CALR).
|
29192651 |
2018 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Additionally, subgroup analyses showed the pooled HR for OS was 0.93(95%CI: 0.44 to 1.98; P=0.849) in WHO-classified CMML patients and 1.02(95%CI: 1.02 to 3.46; p=0.042) in studies evaluated TET2 expression level.
|
28476038 |
2017 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
SRSF2 and U2AF1 along with TET2 (48%) and ASXL1 (38%) are frequently affected by somatic mutations in chronic myelomonocytic leukemia, quite distinctly from the profile seen in juvenile myelomonocytic leukemia.
|
22773603 |
2013 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Comparison of clonal expansions of TET2 mutations in MDS, MPN, and CMML, together with functional invalidation of TET2 in sorted progenitors, suggests a causative link between early clonal dominance and skewed granulomonocytic differentiation.
|
23319568 |
2013 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Since human MDS and CMML are driven by TET2 mutations and associated with chronic inflammation, we hypothesized that arginase enzymatic activity and ARG1 expression would be increased in human MDS/CMML bone marrow.
|
29227812 |
2018 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A TET2 deletion was found in one patient with chronic myelomonocytic leukemia suggesting that fluorescence in situ hybridization may have a role in identification of TET2 deletions, at least in this group of patients.
|
21087791 |
2011 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Sequencing of TET2 in 408 paired tumor/normal samples distinguished between 68 somatic mutations and 6 novel single nucleotide polymorphisms and identified TET2 mutations in MPN (27 of 354, 7.6%), CMML (29 of 69, 42%), AML (11 of 91, 12%), and M7 AML (1 of 28, 3.6%) samples.
|
19420352 |
2009 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic TET2 mutations are frequently observed in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemias (AML) and secondary AML (sAML).
|
21057493 |
2010 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
MP-CMML patients had significantly shorter overall survival (OS; <i>P</i> < .0001; hazard ratio: 0.53, 95% confidence interval: 0.42-0.65) and median duration to acute myeloid leukemia (AML) transformation (<i>P</i> < .0001; 15.2 vs 22.0 months) compared with MDS-CMML patients.
|
30054307 |
2018 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Notably, the TET2 mutation was also identified in peripheral blood cells in the disease-free period with the same allelic frequency as CMML and FL cells, but not in a germ-line control, indicating that the TET2 mutation occurred somatically in the initiating clone for both malignant cells.
|
29666007 |
2018 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.
|
27353473 |
2017 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
|
26771811 |
2016 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Tet methylcytosine dioxygenase 2 (TET2) is one of the earliest and most frequently mutated genes in clonal hematopoiesis of indeterminate potential (CHIP) and myeloid cancers, including myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
|
28826859 |
2017 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].
|
22017486 |
2012 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
TET2 mutations do not explain genome-wide differences in DNA methylation in CMML, and we found few and inconsistent differences at CGIs between TET2-WT and TET2-MT cases.
|
25972343 |
2015 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Using bisulfite pyrosequencing, global methylation measured by the LINE-1 assay and DNA methylation levels of 10 promoter CpG islands frequently abnormal in myeloid leukemia were not different between TET2 mutants and wild-type CMML cases.
|
22395470 |
2012 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate the presence of aberrant DNA methylation in CMML and identifies TET2 mutant CMML as a biologically distinct disease subtype with a different epigenetic profile.
|
22328940 |
2012 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
TET2 mutations were distributed across all entities but were most frequent in suspected chronic myelomonocytic leukemia (77.8%).
|
22511494 |
2012 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Concurrent Tet2 loss and Nras<sup>G12D</sup> expression in hematopoietic cells induced myeloid transformation, with a fully penetrant, lethal chronic myelomonocytic leukemia (CMML), which was serially transplantable.
|
29275866 |
2018 |
Leukemia, Myelomonocytic, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This large, multi-institutional study (n = 1084), investigated the TET2 mutational landscape and prognostic implications of the number, type, and location of TET2<sup>MT</sup> and the epistatic relationship with other somatic events in chronic myelomonocytic leukemia (CMML).
|
31836856 |
2019 |